Cited by 32Body Image and Dysmorphia StudiesPsychosomatic Disorders and Their TreatmentsObsessive-Compulsive Spectrum Disorders

New perspectives in the treatment of body dysmorphic disorder

Open access
Hong, Kevin, Nezgovorova, Vera, Hollander, Eric·2018·F1000Research

Abstract

Body dysmorphic disorder (BDD) is a disabling illness with a high worldwide prevalence. Patients demonstrate a debilitating preoccupation with one or more perceived defects, often marked by poor insight or delusional convictions. Multiple studies have suggested that selective serotonin reuptake inhibitors and various cognitive behavioral therapy modalities are effective first-line treatments in decreasing BDD severity, relieving depressive symptoms, restoring insight, and increasing quality of life. Selective serotonin reuptake inhibitors have also recently been shown to be effective for relapse prevention. This review provides a comprehensive summary of the current understanding of BDD, including its clinical features, epidemiology, genetics, and current treatment modalities. Additional research is needed to fully elucidate the relationship between BDD and comorbid illnesses such as obsessive–compulsive-related disorders and depression and to develop therapies for refractory patients and those who have contraindications for pharmacological intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12688/f1000research.13700.1

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SSRIs including fluoxetine, sertraline, and escitalopram significantly reduce BDD-related obsessive thoughts and compulsive behaviors.

    “SSRIs, including fluoxetine, sertraline, and escitalopram, have been demonstrated to significantly reduce BDD-related obsessive thoughts and compulsive behaviors [124].”

    From The Impact of Social Media & Technology on Child and Adolescent Mental Health (2025) · cites this paper as [124]

    The Treatment section identifies fluoxetine and escitalopram as serotonin reuptake inhibitors used for BDD and reports reduced BDD symptoms with escitalopram treatment. The copy does not identify sertraline or demonstrate a significant reduction specifically in BDD-related obsessive thoughts and compulsive behaviors; its discussion of improved repetitive behaviors with fluoxetine concerns adults with autism, not BDD. No page numbers are available in the indexed passages. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • BDD-ben a szerotonin-visszavételt gátló antidepresszívumok (SSRI) az elsőként választandó gyógyszerek.

    “BDD-ben a szerotonin-visszavételt gátló antidepresszívumok (röviden, angolul: SSRI) az els ő ként választandó gyógyszerek (Krebs, Fernández de la Cruz és Mataix-Cols, 2017; Hong, Nezgovorova és Hollander, 2018; Hong, Nezgovorova, Uzunova, Schlussel és Hollander, 2019).”

    From A testdiszmorfiás zavar pszichológiai vonatkozásai (2023) · cites this paper as Hong, Nezgovorova és Hollander, 2018

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hong, K., Nezgovorova, V., & Hollander, E.
Affiliations
Albert Einstein College of Medicine (US)
Corresponding author
Hollander, Eric
Venue
F1000Research
Published
2018-03-23
Volume
7
Pages
361
ISSN
2046-1402 (ISSN-L)
OpenAlex
W2792573455
Cited by
31
References
79
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 1
FWCI
0.55
Type
journal article
Language
en
Open access
Locations
  • F1000Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (UL1TR001073)
  • National Center for Advancing Translational Sciences
Topics
  • Social Sciences › Psychology › Clinical Psychology › Body Image and Dysmorphia Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Keywords
body dysmorphic disorder, treatment, selective serotonin reuptake inhibitors, cognitive behavioral therapy, insight, relapse prevention, depression, obsessive-compulsive and related disorders, comorbidities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review